statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Bitcoin

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Invesco QQQ Trust Series 1

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

--2023 Form 10-K/A and Q1 2024 Form 10-Q filed today-- --2024 Annual Meeting of Shareholders will be June 18, 2024 -- MIAMI, FL, April 01, 2024 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a...

Veru Announces Date of 2024 Annual Meeting of Shareholders

Raymond James started coverage on shares of Veru (NASDAQ:VERU - Free Report) in a research report sent to investors on Thursday morning, Marketbeat Ratings reports. The brokerage issued an outperform...

Veru (NASDAQ:VERU) Coverage Initiated at Raymond James

Sophiris Bio (OTCMKTS:SPHS  Get Free Report) and Veru (NASDAQ:VERU  Get Free Report) are both small-cap medical companies, but which is the superior business? We will compare the two...

Financial Survey: Sophiris Bio (OTCMKTS:SPHS) vs. Veru (NASDAQ:VERU)

--Restated historical financial statements expected to be filed no later than April 15, 2024-- --2024 Annual Meeting of Shareholders to follow financial statements filings-- MIAMI, FL, March 22...

Veru Reschedules Annual Meeting of Shareholders

Some of the market headwinds will soon become tailwinds, says Dan Veru...

Some of the market headwinds will soon become tailwinds, says Dan Veru

MIAMI, March 12, 2024 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for preserving muscle for high quality...

Veru Announces the Appointment of Louis Aronne MD as Chief Medical Advisor for its Enobosarm Program for High Quality Weight Loss

MIAMI, FL, Feb. 27, 2024 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for preserving muscle for higher...

Veru Announces Notification from Nasdaq Related to Delayed Quarterly Report on Form 10-Q

See the rest of the story here.

thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...

Veru announces new scientific advisory board for enobosarm program

MIAMI, Feb. 20, 2024 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for preserving muscle for higher...

Veru Announces New Scientific Advisory Board for its Enobosarm Program for High Quality Weight Loss

Company receives FDA IND clearance for the development of enobosarm in combination with GLP-1 drugs for potentially higher quality weight loss than has been shown with GLP-1 drug alone Company to...

Veru Reports Fiscal 2024 First Quarter Financial Highlights

Veru, Inc. is a late clinical stage biopharmaceutical company focused on developing novel medicines for the treatment of metabolic diseases, oncology, and ARDS. The company’s drug development program includes two late-stage novel small molecules, enobosarm and sabizabulin. Enobosarm, a selective androgen receptor modulator (SARM), is being developed for two indications: (i) Phase 2b clinical study of enobosarm as a treatment to augment fat loss and to prevent muscle loss in sarcopenic obese or overweight elderly patients receiving a GLP-1 RA who are at-risk for developing muscle atrophy and muscle weakness and (ii) subject to the availability of sufficient funding, Phase 3 clinical trial of enobosarm for the treatment of androgen receptor positive (AR+), estrogen receptor positive (ER+) and human epidermal growth factor receptor 2 negative (HER2-) metastatic breast cancer in the 2nd line setting. Sabizabulin, a microtubule disruptor, is being developed as a Phase 3 clinical trial for the treatment of hospitalized patients with viral-induced ARDS. The company was founded by William R. Gargiulo, Jr., O. B. Parrish, and Harry Fisch in 1971 and is headquartered in Miami, FL.

Volume	2.33M
52-Wk High	$1.92
52-Wk Low	$0.36

Period	Estimated	Reported	Surprise	Result
Q2'24	-$0.06	--	--	N/A
Q1'24	-$0.08	--	--	N/A
Q4'23	-$0.24	--	--	N/A
Q3'23	-$0.20	$0.07	134.43%	BEAT
Q2'23	-$0.33	-$0.48	-44.36%	MISSED

VERU Veru Inc

About

Feed

News

Sentiment

Earnings

Fundamentals